| $381M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $114,341 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Blume-Jensen Peter | President and CEO | 1 | $82,124 | 0 | $0 | $82,124 |
| Devroe Eric | Chief Operating Officer | 1 | $17,218 | 0 | $0 | $17,218 |
| Levy Adam D. | Chief Financial Officer | 1 | $14,999 | 0 | $0 | $14,999 |
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Over the last 12 months, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $114,341 and sold $0 worth of Acrivon Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $22.49M and sold $1.93M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Blume-Jensen Peter (President and CEO) — $82,124. Devroe Eric (Chief Operating Officer) — $17,218. Levy Adam D. (Chief Financial Officer) — $14,999.
The last purchase of 49,000 shares for transaction amount of $82,124 was made by Blume-Jensen Peter (President and CEO) on 2026‑01‑14.
| 2026-01-14 | Blume-Jensen Peter | President and CEO | 49,000 0.1422% | $1.68 | $82,124 | -9.29% | ||
| 2026-01-14 | Levy Adam D. | Chief Financial Officer | 8,832 0.026% | $1.70 | $14,999 | -9.29% | ||
| 2026-01-13 | Devroe Eric | Chief Operating Officer | 10,000 0.0321% | $1.72 | $17,218 | -2.06% | ||
| 2025-05-01 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 298,886 0.9604% | $1.34 | $400,507 | +21.05% | |
| 2025-04-30 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 437,881 1.4067% | $1.41 | $617,412 | +15.00% | |
| 2025-04-29 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 250,000 0.7808% | $1.41 | $352,500 | +11.11% | |
| 2025-04-28 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 215,283 0.6532% | $1.56 | $335,841 | +3.23% | |
| 2025-04-25 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1.05M 3.9999% | $1.95 | $2.06M | -2.44% | |
| 2024-04-11 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 2.35M 8.4743% | $8.50 | $20M | -22.39% | ||
| 2023-06-26 | Sale | Chione Ltd | 10 percent owner | 16 <0.0001% | $12.93 | $207 | -48.66% | |
| 2023-06-15 | Sale | Chione Ltd | 10 percent owner | 2,056 0.0106% | $12.14 | $24,960 | -39.33% | |
| 2023-06-14 | Sale | Chione Ltd | 10 percent owner | 893 0.0046% | $12.13 | $10,832 | -38.40% | |
| 2023-06-13 | Sale | Chione Ltd | 10 percent owner | 3,000 0.0156% | $12.30 | $36,900 | -40.28% | |
| 2023-06-12 | Sale | Chione Ltd | 10 percent owner | 2,000 0.0105% | $12.34 | $24,680 | -40.91% | |
| 2022-11-17 | RA CAPITAL MANAGEMENT, L.P. | 3.39M 17.9519% | $12.50 | $42.37M | -21.95% | |||
| 2022-11-17 | Chione Ltd | 10 percent owner | 400,000 2.1185% | $12.50 | $5M | -21.95% |
| Blume-Jensen Peter | President and CEO | 2095771 6.6414% | $2.89M | 1 | 0 | |
| Devroe Eric | Chief Operating Officer | 75308 0.2386% | $103,925.04 | 1 | 0 | |
| Levy Adam D. | Chief Financial Officer | 20983 0.0665% | $28,956.54 | 1 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | 4384206 13.8933% | $6.05M | 1 | 0 | <0.0001% | |
| Chione Ltd | 10 percent owner | 3848632 12.1961% | $5.31M | 1 | 5 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 3104139 9.8369% | $4.28M | 1 | 5 | <0.0001% |
$2,542,362 | 111 | 11.81% | $47.35M | |
$155,630,608 | 79 | -24.53% | $51.15M | |
$693,326 | 47 | -16.18% | $50.26M | |
$95,303,339 | 30 | -13.78% | $32.66M | |
$523,320 | 24 | 94.37% | $33.66M | |
$241,165 | 22 | -16.72% | $32.94M | |
$226,127 | 22 | -27.62% | $46.33M | |
$3,556,951 | 18 | 9.64% | $36.61M | |
$13,486,672 | 11 | 82.26% | $36.61M | |
$31,610,161 | 9 | -73.83% | $51.94M | |
$5,306,958 | 5 | 11.70% | $45.98M | |
$208,889 | 5 | 44.22% | $45.93M | |
$104,699 | 5 | -12.61% | $37.89M | |
$657,791 | 4 | -52.05% | $33.84M | |
Acrivon Therapeutics, Inc. Common Stock (ACRV) | $67,369,250 | 3 | -22.09% | $43.55M |
$4,999,995 | 1 | -67.50% | $52.83M | |
$150,000 | 1 | 5.48% | $49.5M | |
$30,190 | 1 | -42.39% | $32.87M | |
$4,030 | 1 | 9.14% | $41.45M |
| Increased Positions | 24 | +50% | 2M | +10.54% |
| Decreased Positions | 17 | -35.42% | 713,771 | -4.08% |
| New Positions | 8 | New | 136,860 | New |
| Sold Out Positions | 7 | Sold Out | 80,737 | Sold Out |
| Total Postitions | 55 | +14.58% | 19M | +6.46% |
| Ra Capital Management, L.P. | $20,518.00 | 26.06% | 8.34M | 0 | 0% | 2025-09-30 |
| Sands Capital Alternatives, Llc | $5,222.00 | 6.63% | 2.12M | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $3,792.00 | 4.82% | 1.54M | -354,193 | -18.69% | 2025-09-30 |
| Wellington Management Group Llp | $2,185.00 | 2.78% | 888,130 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $1,681.00 | 2.13% | 683,218 | +682,763 | +150,057.8% | 2025-09-30 |
| Vanguard Group Inc | $1,540.00 | 1.96% | 626,148 | +32,901 | +5.55% | 2025-09-30 |
| Renaissance Technologies Llc | $1,534.00 | 1.95% | 623,400 | +114,105 | +22.41% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $997.00 | 1.27% | 405,237 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $814.00 | 1.03% | 330,957 | -76,665 | -18.81% | 2025-09-30 |
| Two Sigma Investments, Lp | $785.00 | 1% | 319,205 | +138,033 | +76.19% | 2025-09-30 |